An innovative approach for the characterization of the isoforms of a monoclonal antibody product

References

• Brekke OH, Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov 2003; 2:52 - 62; PMID: 12509759; http://dx.doi.org/10.1038/nrd984
   PubMed Web of Science ®Google Scholar
• Bebbington C, Yarranton G. Antibodies for the treatment of bacterial infections: current experience and future prospects. Curr Opin Biotechnol 2008; 19:613 - 619; PMID: 19000762; http://dx.doi.org/10.1016/j.cop-bio.2008.10.002
   PubMed Web of Science ®Google Scholar
• Aires da Silva F, Corte-Real S, Goncalves J. Recombinant antibodies as therapeutic agents: pathways for modeling new biodrugs. BioDrugs 2008; 22:301 - 314; PMID: 18778112
   PubMed Web of Science ®Google Scholar
• Jefferis R, Lund J, Mizutani H, Nakagawa H, Kawazoe Y, Arata Y, et al. A comparative study of N-linked oligosaccharide structures of human IgG subclass proteins. Biochem J 1990; 268:529 - 537; PMID: 2363690
   PubMed Web of Science ®Google Scholar
• Jefferis R, Lund J. Glycosylation of antibody molecules. Structural and functional significance. Chem Immunol 1997; 65:111 - 128; PMID: 9018875; http://dx.doi.org/10.1159/000319352
   PubMed Web of Science ®Google Scholar
• Manning MC, Patel K, Borchardt R. Stability of protein pharmaceuticals. Pharm Res 1989; 6:903 - 918; PMID: 2687836; http://dx.doi.org/10.1023/A:1015929109894
   PubMed Web of Science ®Google Scholar
• Volkin DB, Mach H, Middaugh CR. Degradative covalent reactions important to protein stability. Mol Biotechnol 1997; 8:105 - 122; PMID: 9406181
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration. Points to consider in the manufacture and testing of monoclonal antibody products for human use 1997; 2 28 US department of Health and Human services, FDA Center for Biologics Evaluation and Research
   Google Scholar
• Reichert JM. Antibody-based therapeutics to watch in 2011. MAbs 2011; 3:76 - 99; PMID: 21051951; http://dx.doi.org/10.4161/mabs.3.1.13895
   PubMed Web of Science ®Google Scholar
• Reichert JM. Metrics for antibody development. MAbs 2010; 2:695 - 700; PMID: 20930555; http://dx.doi.org/10.4161/mabs.2.6.13603
   PubMed Web of Science ®Google Scholar
• Lansigan F, Foss FM. Current and emerging treatment strategies for cutaneous T-cell lymphoma. Drugs 2010; 70:273 - 286; PMID: 20166766; http://dx.doi.org/10.2165/11532190
   PubMed Web of Science ®Google Scholar
• Eggermont AM, Robert C. New drugs in melanoma: It's whole new world. Eur J Cancer 2011; 47:2150 - 2157; PMID: 21802280; http://dx.doi.org/10.1016/j.ejca.2011.06.052
   PubMed Web of Science ®Google Scholar
• Vlasak J, Ionescu R. Heterogeneity of monoclonal antibodies revealed by charge sensitive methods. Curr Pharm Biotechnol 2008; 9:468 - 481; PMID: 19075686; http://dx.doi.org/10.2174/138920108786786402
   PubMed Web of Science ®Google Scholar
• Meert CD, Brady LJ, Guo A, Balland A. Characterization of antibody charge heterogeneity resolved by preparative immobilized pH gradients. Anal Chem 2010; 82:3510 - 3518; PMID: 20364842; http://dx.doi.org/10.1021/ac902408r
   PubMed Web of Science ®Google Scholar
• Hooker AD, Goldman MH, Markham MH, James DC, Ison AP, Bull AT, et al. N-glycans of recombinant human interferon-gamma change during batch culture of Chinese hamster ovary cells. Biotechnol Bioeng 1995; 48:639 - 648; PMID: 18623533; http://dx.doi.org/10.1002/bit.260480612
   PubMed Web of Science ®Google Scholar
• Gu X, Xie L, Harmon BJ, Wang DI. Influence of Primatone RL supplementation on sialylation of recombinant human interferon-gamma produced by Chinese hamster ovary cell culture using serum-free media. Biotechnol Bioeng 1997; 56:353 - 360; PMID: 18642238; http://dx.doi.org/10.1002/(SICI)1097-0290(19971120)56:4353::AID-BIT13.0.CO;2-N
   PubMed Web of Science ®Google Scholar
• Patel TP, Parkeh RB, Moellering BJ, Prior CP. Different culture methods lead to differences in glycosylation of a murine IgG monoclonal antibody. Biochem J 1992; 285:839 - 845; PMID: 1497622
   PubMed Web of Science ®Google Scholar
• Fang Y, Dumont L, Larsen B. Real time isoform analysis by two dimensional chromatography of a monoclonal antibody during bioreactor fermentations. J Chromatogr A 1998; 816:39 - 47; PMID: 9741099; http://dx.doi.org/10.1016/S0021-9673(98)00032-6
   PubMed Web of Science ®Google Scholar
• Kroon DJ, Baldwin-Ferro A, Lalan L. Identification of sites of degradation in a therapeutic monoclonal antibody by peptide mapping. Pharm Res 1992; 9:1386 - 1393; PMID: 1475223; http://dx.doi.org/10.1023/A:1015894409623
   PubMed Web of Science ®Google Scholar
• Bornstein P, Balian G. Hirs CHW, Serge N, Timasheff N. Cleavage at Asn-Gly bonds with hydroxylamine. Methods in Enzymol. Vol XLVIII, Enzyme Structure (Part E) 1997; New York Academic Press
   Google Scholar
• Stephenson RC, Clarke S. Succimide formation from aspartyl and asparaginal peptides as a model for spontaneous degradation of proteins. J Biol Chem 1989; 264:6164 - 6170; PMID: 2703484
   PubMed Web of Science ®Google Scholar
• Perkins M, Theiler R, Lunte S, Jeschke M. Determination of the origin of charge heterogeneity in a murine monoclonal antibody. Pharm Res 2000; 17:1110 - 1117; PMID: 11087044; http://dx.doi.org/10.1023/A:1026461830617
   PubMed Web of Science ®Google Scholar
• Clarke S. Propensity for spontaneous succinimide formation from aspartyl and asparaginyl residues in cellular proteins. Int J Pept Protein Res 1987; 30:808 - 821; PMID: 3440704; http://dx.doi.org/10.1111/j.1399-3011.1987.tb03390.x
   PubMedGoogle Scholar
• Kossiakoff AA. Tertiary structure is a principal determinant to protein deamidation. Science 1988; 240:191 - 194; PMID: 3353715; http://dx.doi.org/10.1126/science.3353715
   PubMed Web of Science ®Google Scholar
• Tyler-Cross R, Schirch V. Effects of amino acid sequence, buffers and ionic strength on the rate and mechanism of deamidation of asparagines residues in small peptides. J Biol Chem 1991; 266:22549 - 22556; PMID: 1939272
   PubMed Web of Science ®Google Scholar
• Zhang W, Czuprryn M. Analysis of isoaspartate in a recombinant monoclonal antibody and its charge isoforms. J Pharm Biomed Anal 2003; 30:1479 - 1490; PMID: 12467919; http://dx.doi.org/10.1016/S0731-7085(02)00479-X
   PubMed Web of Science ®Google Scholar
• Harris RJ. Processing of C-terminal lysine and arginine residues of proteins isolated from mammalian cell culture. J Chromatogr A 1995; 705:129 - 134; PMID: 7620566; http://dx.doi.org/10.1016/0021-9673(94)01255-D
   PubMed Web of Science ®Google Scholar
• Tous GI, Wei Z, Feng J, Bilbulin S, Bowen S, Smith J, et al. Characterization of a novel modification to monoclonal antibodies: thioether cross-link of heavy and light chains. Anal Chem 2005; 77:2675 - 2682; PMID: 15859580; http://dx.doi.org/10.1021/ac0500582
   PubMed Web of Science ®Google Scholar
• Cohen SL, Price C, Vlasak J. β-elimination and peptide bond hydrolysis: two distinct mechanisms of human IgG1 hinge fragmentation upon storage. J Am Chem Soc 2007; 129:6976 - 6977; PMID: 17500521; http://dx.doi.org/10.1021/ja0705994
   PubMed Web of Science ®Google Scholar
• Pristatsky P, Cohen SL, Krantz D, Acevedo J, Ionescu R, Vlasak J. Evidence for trisulfide bonds in a recombinant vaient of human IgG2 monoclonal antibody. Anal Chem 2009; 81:6148 - 6155; PMID: 19591437; http://dx.doi.org/10.1021/ac9006254
   PubMed Web of Science ®Google Scholar
• Rush RS, Derby PL, Smith DM, Merry C, Rogers G, Rhode MF. Micro-hertogeneity of erythropoietin carbohydrate structure. Anal Chem 1995; 67:1442 - 1452; PMID: 7741215; http://dx.doi.org/10.1021/ac00104a022
   PubMed Web of Science ®Google Scholar
• Catlin DH, Breidbach A, Elliot S, Glaspy J. Comparison of isoelectric patterns of Darbepoeetin Alfa, recombinant erythropoietin and endogeneous erythropoietin from human urine. Clin Chem 2002; 11:2057 - 2059
   Google Scholar
• Qian J, Liu T, Yang L, Daus A, Crowley R, Zhou Q. Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted lase desorption/ionization hybrid quadrupole-quadrupole time-of-fight tandem mass spectrometry and sequential enzymatic digestion. Anal Biochem 2007; 364:8 - 18; PMID: 17362871; http://dx.doi.org/10.1016/j.ab.2007.01.023
   PubMed Web of Science ®Google Scholar
• Natsume A, Niwa R, Satoh M. Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC. Drug Des Devel Ther 2009; 3:7 - 16; PMID: 19920917
   PubMed Web of Science ®Google Scholar
• Peipp M, Lammerts JJ, van Bueren L, Schneider-Merck TJ, Bleeker WWK, Dechant M, et al. Antibody fucosylation differently impacts cytotoxicity mediated by NK and PMN effector cells. Blood 2008; 112:2390 - 2399; PMID: 18566325; http://dx.doi.org/10.1182/blood-2008-03-144600
   PubMed Web of Science ®Google Scholar
• Kaneko Y, Nimmerijahn F, Ravetch JV. Anti inflammatory activity of immunoglobulin G resulting from Fc sialyation. Science 2006; 313:670 - 673; PMID: 16888140; http://dx.doi.org/10.1126/science.1129594
   PubMed Web of Science ®Google Scholar
• Scallon BJ, Tam SH, McCarthy SG, Cai AN, Raju TS. Higher levels of sialyated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol Immunol 2007; 44:1524 - 1534; PMID: 17045339; http://dx.doi.org/10.1016/j.molimm.2006.09.005
   PubMed Web of Science ®Google Scholar
• Naso MF, Tam SH, Scallon BJ, Raju TS. Engineering host cell lines to reduce terminal sialyation of secreted antibodies. MAbs 2010; 2:519 - 527; PMID: 20716959; http://dx.doi.org/10.4161/mabs.2.5.13078
   PubMed Web of Science ®Google Scholar
• Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody dependent cellular cytotoxicity. J Biol Chem 2003; 278:3466 - 3473; PMID: 12427744; http://dx.doi.org/10.1074/jbc.M210665200
   PubMed Web of Science ®Google Scholar
• Weinberg W, Fraizer-Jesson MR, Wu WJ, Weir A, Hartsough M, Keegan P, et al. Development and regulation of monoclonal antibody products: Challenges and opportunities. Cancer Metastasis Rev 2005; 24:569 - 584; PMID: 16408162; http://dx.doi.org/10.1007/s10555-005-6196-y
   PubMed Web of Science ®Google Scholar